

ValÃ©rie Fonteyne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/824939/publications.pdf>

Version: 2024-02-01

98
papers

4,206
citations

147801

31
h-index

114465

63
g-index

100
all docs

100
docs citations

100
times ranked

4835
citing authors

#	ARTICLE	IF	CITATIONS
1	Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 446-453.	1.6	972
2	Radiotherapy for renal-cell carcinoma. <i>Lancet Oncology</i> , The, 2014, 15, e170-e177.	10.7	226
3	Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. <i>Radiation Oncology</i> , 2014, 9, 135.	2.7	220
4	ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 49-61.	0.6	157
5	Intensity-Modulated Radiotherapy as Primary Therapy for Prostate Cancer: Report on Acute Toxicity After Dose Escalation With Simultaneous Integrated Boost to Intraprostatic Lesion. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 799-807.	0.8	132
6	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
7	Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. <i>Prostate</i> , 2014, 74, 297-305.	2.3	120
8	Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. <i>European Urology</i> , 2018, 73, 40-50.	1.9	107
9	Surveillance or metastasis-directed Therapy for Oligometastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. <i>BMC Cancer</i> , 2014, 14, 671.	2.6	106
10	Volumetric Arc Therapy and Intensity-Modulated Radiotherapy for Primary Prostate Radiotherapy With Simultaneous Integrated Boost to Intraprostatic Lesion With 6 and 18 MV: A Planning Comparison Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 920-926.	0.8	90
11	Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2019, 75, 707-711.	1.9	89
12	A Matched Control Analysis of Adjuvant and Salvage High-Dose Postoperative Intensity-Modulated Radiotherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1316-1322.	0.8	84
13	Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 10-10.	1.6	82
14	Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: The need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. <i>Radiotherapy and Oncology</i> , 2007, 84, 156-163.	0.6	80
15	High-Dose Salvage Intensity-Modulated Radiotherapy With or Without Androgen Deprivation After Radical Prostatectomy for Rising or Persisting Prostate-Specific Antigen: 5-Year Results. <i>European Urology</i> , 2011, 60, 842-849.	1.9	74
16	Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: Report on acute toxicity. <i>Radiotherapy and Oncology</i> , 2006, 80, 78-81.	0.6	70
17	What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging?. <i>European Radiology</i> , 2016, 26, 1098-1107.	4.5	63
18	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 436-444.	1.9	60

#	ARTICLE	IF	CITATIONS
19	Intensity-Modulated Arc Therapy with Simultaneous Integrated Boost in the Treatment of Primary Irresectable Cervical Cancer. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 799-807.	2.0	54
20	Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. <i>BJU International</i> , 2017, 120, 815-821.	2.5	53
21	REQUIRE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 138, 59-67.	0.6	53
22	Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. <i>European Urology</i> , 2019, 75, 826-833.	1.9	48
23	Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2009, 92, 42-47.	0.6	47
24	Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Trial. <i>Urology</i> , 2017, 106, 146-152.	1.0	42
25	Delineation of the Postprostatectomy Prostate Bed Using Computed Tomography: Interobserver Variability Following the EORTC Delineation Guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e143-e149.	0.8	41
26	Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 393-401.	2.0	39
27	High-Dose Adjuvant Radiotherapy After Radical Prostatectomy With or Without Androgen Deprivation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 960-965.	0.8	38
28	A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 294-301.	5.4	38
29	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. <i>European Urology</i> , 2018, 73, 512-518.	1.9	36
30	Radiation Dosimetry and Biodistribution of ¹⁸ F-PSMA-11 for PET Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1736-1742.	5.0	34
31	Integrated models for the prediction of late genitourinary complaints after high-dose intensity modulated radiotherapy for prostate cancer: Making informed decisions. <i>Radiotherapy and Oncology</i> , 2014, 112, 95-99.	0.6	33
32	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. <i>Cancer Treatment Reviews</i> , 2021, 98, 102206.	7.7	30
33	Hypofractionated Intensity-Modulated Arc Therapy for Lymph Node Metastasized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1013-1020.	0.8	29
34	A systematic review of exercise and psychosocial rehabilitation interventions to improve health-related outcomes in patients with bladder cancer undergoing radical cystectomy. <i>Clinical Rehabilitation</i> , 2018, 32, 594-606.	2.2	29
35	Hypofractionated High-Dose Radiation Therapy for Prostate Cancer: Long-Term Results of a Multi-Institutional Phase II Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e483-e490.	0.8	28
36	Rectal toxicity after intensity modulated radiotherapy for prostate cancer: Which rectal dose volume constraints should we use?. <i>Radiotherapy and Oncology</i> , 2014, 113, 398-403.	0.6	28

#	ARTICLE	IF	CITATIONS
37	Acute Radiation-Induced Nocturia in Prostate Cancer Patients Is Associated With Pretreatment Symptoms, Radical Prostatectomy, and Genetic Markers in the TGF β 21 Gene. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 393-399.	0.8	27
38	Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: Early late toxicity and 3-year clinical outcome. <i>Radiotherapy and Oncology</i> , 2013, 109, 229-234.	0.6	27
39	Metastatic burden in newly diagnosed hormone-naïve metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 158.e13-158.e20.	1.6	27
40	Salvage Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	26
41	Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 88-97.	7.7	26
42	Elective nodal radiotherapy in prostate cancer. <i>Lancet Oncology</i> , The, 2021, 22, e348-e357.	10.7	26
43	Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: Analysis of genito-urinary and rectal toxicity. <i>Radiotherapy and Oncology</i> , 2016, 119, 398-404.	0.6	24
44	The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry. <i>European Urology Open Science</i> , 2021, 29, 68-76.	0.4	23
45	Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 914-923.	5.4	23
46	The Rationale for Post-Operative Radiation in Localized Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 19-30.	0.4	22
47	Hyperbaric oxygen therapy for radiation cystitis after pelvic radiotherapy: Systematic review of the recent literature. <i>International Journal of Urology</i> , 2020, 27, 98-107.	1.0	21
48	The Outcome for Patients With Pathologic Node-Positive Prostate Cancer Treated With Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy: A Case-Matched Analysis of pN1 and pN0 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 323-332.	0.8	19
49	Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: Toxicity and matched case comparison with postoperative prostate bed-only radiotherapy. <i>Radiotherapy and Oncology</i> , 2013, 109, 222-228.	0.6	17
50	Developments in External Beam Radiotherapy for Prostate Cancer. <i>Urology</i> , 2013, 82, 5-10.	1.0	16
51	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 541281.	2.8	15
52	Agreement of Gleason Score on Prostate Biopsy and Radical Prostatectomy Specimen: Is There Improvement With Increased Number of Biopsy Cylinders and the 2005 Revised Gleason Scoring?. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 160-166.	1.9	14
53	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. <i>European Urology</i> , 2019, 76, 443-449.	1.9	14
54	Understanding physical activity behavior in patients with bladder cancer before and after radical cystectomy: a qualitative interview study. <i>Clinical Rehabilitation</i> , 2019, 33, 750-761.	2.2	14

#	ARTICLE	IF	CITATIONS
55	Health-related quality of life overview after different curative treatment options in muscle-invasive bladder cancer: an umbrella review. <i>Quality of Life Research</i> , 2020, 29, 2887-2910.	3.1	14
56	Whole pelvis radiotherapy for pathological node-positive prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 444-451.	2.0	13
57	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. <i>European Urology</i> , 2018, 74, 134-137.	1.9	13
58	Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11256.	1.0	12
59	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2021, 159, 241-248.	0.6	11
60	Contemporary minimally-invasive extended pelvic lymph node dissection for prostate cancer before curative radiotherapy: Prospective standardized analysis of complications. <i>International Journal of Urology</i> , 2014, 21, 1138-1143.	1.0	10
61	Clinical pathway improves implementation of evidence-based strategies for the management of androgen deprivation therapy-induced side effects in men with prostate cancer. <i>BJU International</i> , 2018, 121, 610-618.	2.5	10
62	Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 2565-2571.	2.2	10
63	Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial. <i>BMC Cancer</i> , 2021, 21, 1113.	2.6	10
64	Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2022, 168, 75-82.	0.6	10
65	Improving Positioning in High-Dose Radiotherapy for Prostate Cancer: Safety and Visibility of Frequently Used Gold Fiducial Markers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 46-52.	0.8	9
66	Prostate magnetic resonance spectroscopic imaging at 1.5tesla with endorectal coil versus 3.0tesla without endorectal coil: comparison of spectral quality. <i>Clinical Imaging</i> , 2015, 39, 636-641.	1.5	9
67	Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience. <i>Acta Oncologica</i> , 2015, 54, 854-861.	1.8	9
68	Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 76-85.	4.4	9
69	Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer Patients. <i>Diagnostics</i> , 2017, 7, 56.	2.6	8
70	The Role of Androgen Receptor Expression in the Curative Treatment of Prostate Cancer with Radiotherapy: A Pilot Study. <i>BioMed Research International</i> , 2015, 2015, 1-8.	1.9	7
71	Rehabilitation interventions to improve patient-reported outcomes and physical fitness in survivors of muscle invasive bladder cancer: a systematic review protocol. <i>BMJ Open</i> , 2017, 7, e016054.	1.9	7
72	Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial. <i>BMC Cancer</i> , 2017, 17, 308.	2.6	7

#	ARTICLE	IF	CITATIONS
73	4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 866-870.	0.8	7
74	Pelvic lymph node dissection in prostate cancer staging: evaluation of morbidity and oncological outcomes. <i>Acta Chirurgica Belgica</i> , 2019, 119, 103-109.	0.4	7
75	Evaluating the Current Place of Radiotherapy as Treatment Option for Patients With Muscle Invasive Bladder Cancer in Belgium. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1159-e1169.	1.9	6
76	Adoption of single fraction radiotherapy for uncomplicated bone metastases in a tertiary centre. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 64-69.	1.7	6
77	Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial. <i>European Urology Focus</i> , 2022, 8, 1238-1245.	3.1	6
78	Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer. <i>Advances in Urology</i> , 2012, 2012, 1-8.	1.3	5
79	Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2351-2352.	1.6	4
80	Readdressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. <i>BJU International</i> , 2019, 124, 35-39.	2.5	4
81	Estimating the incidence of oligorecurrent and potentially salvageable prostate cancer on 18F-Choline PET-CT: Screening phase of the STOMP randomized phase II trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 153-153.	1.6	4
82	Supportive Roles of the Health Care Team Throughout the Illness Trajectory of Bladder Cancer Patients Undergoing Radical Cystectomy: A Qualitative Study Exploring the Patients' Perspectives. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151226.	1.5	4
83	Perspective on cytoreduction and metastasis-directed therapy in node positive and metastatic urothelial carcinoma of the bladder. <i>Translational Andrology and Urology</i> , 2017, 6, 1117-1122.	1.4	3
84	Re: Gaetan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? <i>Eur Urol</i> 2019;76:265-7. <i>European Urology</i> , 2019, 76, e147-e148.	1.9	3
85	PET-CT for staging patients with muscle invasive bladder cancer: is it more than just a fancy tool?. <i>Clinical and Translational Imaging</i> , 2021, 9, 83-94.	2.1	3
86	What is the Optimal Dose, Fractionation and Volume for Bladder Radiotherapy?. <i>Clinical Oncology</i> , 2021, 33, e245-e250.	1.4	3
87	Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic castration-sensitive prostate cancer: A pooled analysis of the STOMP and ORIOLE trials. <i>Journal of Clinical Oncology</i> , 2022, 40, 5025-5025.	1.6	3
88	The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 152.e13-152.e22.	1.6	2
89	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology Oncology</i> , 2021, 4, 301-304.	5.4	2
90	Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging. <i>Molecular Imaging and Biology</i> , 2022, , 1.	2.6	2

#	ARTICLE	IF	CITATIONS
91	Predicting perioperative mortality after radical cystectomy: comorbidity assessment tools are only part of the puzzle. <i>Translational Andrology and Urology</i> , 2019, 8, 781-784.	1.4	1
92	Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this "œcort" is not out of order!. <i>Asian Journal of Andrology</i> , 2021, .	1.6	1
93	Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5096-TPS5096.	1.6	1
94	Selecting candidates for early discharge after radical cystectomy for bladder cancer. <i>Translational Andrology and Urology</i> , 2018, 7, S86-S89.	1.4	0
95	Current Insights in the Management of High-risk Prostate Cancer: Still More Questions than Answers. <i>European Urology</i> , 2019, 75, 61-62.	1.9	0
96	Management of High-Risk/Locally Advanced Disease. , 2013, , 831-842.		0
97	Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 422-422.	1.6	0
98	Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy. <i>Future Oncology</i> , 2020, 16, 1083-1189.	2.4	0